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of CLEC9A genes in Mus musculus, Pan troglodytes, Homo sapiens, Canis 
lupus familiaris, and Macaca mulatta. A database search using part of 
the protein sequence of mouse CLEC9A further suggests the pres-
ence of CLEC9A genes in Rattus norvegicus and Bos taurus (44).



































































Biochemical characterization of mouse DNGR-1 protein. (A) Lysate 
from Phoenix cells stably transfected with a retroviral vector encoding 
HA-tagged mDNGR-1 was Western blotted (WB) with anti-HA before or 
after immunoprecipitation with anti-HA or the indicated anti–mDNGR-1 
antibodies. (B) Western blot using anti–DNGR-1 mAb 397 to probe 
lysates of Phoenix cells expressing (+) or not expressing (–) DNGR-1 
under reducing (right) and nonreducing (left) conditions.
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Mouse DNGR-1 expression is restricted to CD8α+ DCs and pDCs. (A) 
Expression of DNGR-1 in mouse spleen. Splenocytes were stained 
with biotin anti–DNGR-1 7H11 (thick line) or biotin rat IgG1 (thin line; 
isotype-matched control) followed by streptavidin-PE and antibodies to 
CD11c, CD4, CD8α, and Ly6C. CD11c+ and CD11c– cells (upper row) 
or different DC subsets (lower rows) were defined by electronic gating 
as shown on the dot plots. DNGR-1 expression is shown in the corre-
sponding histograms. Numbers indicate percentage of events in gate. 
(B) Expression of DNGR-1 in Flt3L-BMDCs. Histograms show staining 
with anti–DNGR-1 (thick line) compared with isotype-matched control 
(thin line) in B220+ cells corresponding to pDCs, CD24hiCD11blo cells 
corresponding to CD8α+ DCs, and CD24loCD11bhi cells corresponding 
to CD8α– DCs after gating as indicated. Numbers represent percent-
age of events in the indicated gate.
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Specific labeling of CD8α+ DCs and pDCs in vivo with anti–DNGR-1 
mAbs. (A) Mice were injected i.v. with 100 μg of Alexa Fluor 488–con-
jugated anti–DNGR-1 (7H11) or isotype-matched control (rat IgG1), 
and splenocytes were analyzed 1 day later. Dot plots show CD11c 
versus Alexa Fluor 488 in anti–DNGR-1–injected (right panel) or rat 
IgG1–injected (left panel) mice. Contour plots show CD4 versus CD8a 
and Ly6C versus B220 profiles of the CD11chi and CD11cint DNGR-1+ 
populations circled in the dot plot. Numbers represent percentage of 
events in the indicated gate. (B) Mice were injected s.c. with the indi-
cated doses of Alexa Fluor 488–conjugated anti–DNGR-1 (7H11) or a 
single dose of isotype-matched control (rat IgG1, 20 μg/mouse), and 
splenocytes were analyzed 1 day later. Histograms show staining of 
CD8α+ DCs or pDCs obtained with different doses of anti–DNGR-1 
(green line, 0.5 μg; blue line, 2 μg; red line, 5 μg; thick black line, 
20 μg) or isotype-matched control (thin black line). Lower panel shows 
MFI with anti–DNGR-1 divided by that obtained with 20 μg of isotype-
matched control for each DC subset or for non-DC spleen cells.
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anti–DNGR-1–S1 (data not shown). Consistent with target cell 






















Endocytosis of anti–DNGR-1 mAbs in Flt3L BMDCs. (A) Flt3L BMDCs 
were labeled with anti–DNGR-1 7H11 mAbs as detailed in Methods 
and incubated for the indicated times at 4°C or 37°C before adding 
streptavidin-PE. Data represent MFI for the CD24hi subset. Histograms 
show actual staining profiles: thick black line, staining with streptavi-
din-PE immediately after labeling with biotin–anti–DNGR-1; blue line, 
after 2 hours at 4°C; red line, after 2 hours at 37°C; thin black line, 
isotype-matched control. (B) Flt3L BMDCs were labeled with Alexa 
Fluor 488–conjugated anti–DNGR-1 mAbs (7H11, right panels) or iso-
type-matched control (rat IgG1, left panels) and incubated for 2 hours 
at 4°C (upper panels) or 37°C (lower panels) before confocal analysis. 
Image represents a single optical section (<0.7 μm). Note punctate 
staining inside cells incubated at 37°C, indicative of endocytosis. Origi-
nal magnification, ×630.
Figure 
Antigen targeted to DNGR-1 in vivo is cross-presented by CD8α+ DCs. (A) 2 μg S1-conjugated anti–DNGR-1 (7H11) or rat IgG1 isotype-matched 
control mAbs were injected i.v. The next day, CD11c+ and CD11c– spleen cell fractions were prepared, and graded numbers were cultured for 
4 days with CFSE-labeled OT-I cells. Histograms show CFSE profiles of OT-I cells incubated with 25 × 103 CD11c– or CD11c+ splenocytes. 
Right panels show absolute number of OT-I cells per well and IFN-γ content in supernatants. (B) The indicated DC subsets purified from mice 
injected with 2 μg S1–anti–DNGR-1 (7H11) were cultured for 3 days with CFSE-labeled OT-I cells. Response was analyzed as in A. Data are 
representative of at least 3 experiments.
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CTL priming with antigen targeting to DNGR-1 plus anti-CD40. 2 μg S1-conjugated anti–DNGR-1 (7H11) or rat IgG1 isotype-matched control 
mAbs were injected s.c. with or without anti-CD40 (25 μg) as indicated. Target cells were injected 5 days later, and mice were analyzed on day 6. 
(A) In vivo CTL activity as measured by target cell elimination. Histograms show target cell frequency in representative mice from each group 
(CFSElo, 20 nM peptide; CFSEint, 200 nM peptide; CFSEhi, no peptide). Graph shows mean ± SEM of percentage of specific lysis in 1 experi-
ment of 3 (n = 6 mice/group). All groups are shown, but the only one in which killing was detectable was that receiving anti–DNGR-1–S1 plus 
anti-CD40. (B) H-2Kb–SIINFEKL tetramer staining of splenocytes. Left panel shows representative dot plots of tetramer staining versus CD8 
in gated CD8+ Thy1+ T cells. Right panel shows frequency of tetramer-positive CD8+ T cells in 1 experiment of 3 (n = 6 mice/group). (C) In 
vitro restimulation with 1 μM SIINFEKL (PEPTIDE) or medium alone (CTR). Left panel IFN-γ content in supernatants at the end of the 5-day 
culture. Right panel shows specific CTL activity of in vitro–restimulated cells against EL4 targets loaded with 2 μM of SIINFEKL. Data are the 
average + SEM of all cultures (n = 6 mice/group, restimulated individually). P values were calculated using Student’s t test. (D) OVA protein 
conjugated to anti–DNGR-1 induces CTL priming in vivo. Mice were immunized s.c. in the paw with 2 μg anti–DNGR-1 or isotype control anti-
bodies conjugated to OVA protein in the presence of 25 μg of anti-CD40. In vivo killing activity was analyzed as in A using targets loaded with 
200 nM SIINFEKL peptide. Results represent individual mice and the mean for 1 representative experiment out of 3. n = 5; P < 0.01, t test.
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Anti–DNGR-1–S1 plus anti-CD40 is effective in prevention and therapy 
of OVA-expressing B16 melanoma. (A) Tumor prevention experiments 
were carried out as depicted. Data represent lung tumor counts in each 
mouse in 1 experiment out of 2 (n = 6 mice/group). (B) Tumor therapy 
experiments were carried out as depicted. Lower left panel shows rep-
resentative photographs of lungs from mice treated as indicated. Right 
panel shows quantification of tumors in each mouse in 1 representa-
tive experiment out of 3 (n = 6 mice/group). (C) SIINFEKL-H2Kb tetra-
mer-positive cells in spleens from mice depicted in B. Left panels show 
representative histograms of gated CD8+Thy1.2+ splenocytes. Right 
panel shows frequency of tetramer-positive CD8+ T cells in 1 repre-
sentative experiment out of 3 (n = 6 mice/group). (D) Left panel shows 
splenocytes from individual mice depicted in B restimulated in vitro 
with SIINFEKL peptide (1 μM). IFN-γ levels after 5 days of culture are 
indicated for 1 representative experiment out of 3 (n = 6 mice/group). 
Right panel shows CTL activity after restimulation measured as in Fig-
ure 6C. One experiment (n = 6 mice/group, restimulated individually) 
out of 3 is shown. Data are the average ± SEM of all cultures. P values 
were calculated using Student’s t test.
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Immunotherapy of B16 melanoma via targeting of tumor 
antigens to DNGR-1. (A) Tumor therapy experiments 
were carried out as depicted (top panel) using peptides 
encompassing known epitopes of melanocyte differen-
tiation endogenous antigens (Endo: gp100, TRP-1, and 
TRP-2) covalently coupled to anti–DNGR-1 or to an iso-
type-matched control antibody. Poly I:C plus anti-CD40 
was used as adjuvant. Lower left panel shows representa-
tive photographs of lungs from mice treated as indicated. 
Right panel shows quantification of lung tumors in each 
mouse. Data are pooled from 2 independent experiments 
(n = 9 mice/group), and each point represents 1 mouse. 
(B) Splenocytes from individual mice depicted in A were 
restimulated in vitro with the melanocyte differentiation 
antigen peptides used for immunization (10 μM). IFN-γ 
levels after 2 days of culture are shown. Data are pooled 
from 2 independent experiments (n = 9 mice/group). 
P values were calculated using the Mann-Whitney U test.
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Human DNGR-1 expression is restricted to BDCA-3+ blood DCs. (A) Human PBMCs were stained with anti–hDNGR-1 (8F9) or an isotype-
matched control antibody (mouse IgG2a) and counterstained for various leukocyte markers. Histograms show DNGR-1 staining on T cells, 
B cells, monocytes, NK cells, lineage-negative HLA-DR– cells, and lineage-negative HLA-DR+ cells. Numbers indicate the percentage of hDNGR-1+ 
cells in the latter fraction. (B) PBMCs depicted in A were gated on lineage-negative HLA-DR+ cells. Dot plots show staining with anti–DNGR-1 or 
isotype-matched control mAbs against various blood DC subset markers. Numbers represent percentage of cells in each quadrant.
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Endocytosis of anti-human DNGR-1 mAbs by BDCA-3+ blood DCs. 
Human blood BDCA-3+ DCs were stained with anti-hDNGR-1 (8F9) or 
an isotype-matched control antibody (mouse IgG2a), washed, and left 
at 4°C (upper panels) or 37°C (lower panels) for 2 hours before fixation 
and mounting. Representative confocal optical sections (<0.7 μm) are 
shown. Original magnification, ×1260.
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